XDR tuberculosis - Implications for Global Public Health

New England Journal of Medicine

Volumn 356, Issue 7, 2007, Pages 656-659

  Raviglione, Mario C ^a   Smith, Ian M ^b  

^a Stop TB Department ^*

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SHORT SURVEY; SOUTH AFRICA; TUBERCULOSIS;

EID: 33846995990     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068273     Document Type: Article

References (5)

1. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
2. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
3. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;81:430-2.
4. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006;6:710-25.
5. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006;367:952-5.